Baseline characteristics of the validation cohort. (A) Characteristics of the validation cohort as compared with the original and the validation cohorts of the IPSS-M study. (B) Cross heat map for distribution of patients with MDS according to the IPSS-R (x-axis) and the IPSS-M (y-axis) scores. (C) Bar histogram shows the total percentage of patients restratified (upstaged or downstaged) according to the IPSS-M. CC, Cleveland Clinic cohort; CMML, chronic myelomonocytic leukemia; EB, MDS with excess blast; Hb, hemoglobin; IQR, interquartile range; IWG-M, International Working Group for the Prognosis of MDS Cohort; J-MDS, Japanese validation cohort; MLD, multilineage dysplasia; MPN, myeloproliferative neoplasm; Plt, platelet; RS-T, ring sideroblast-thrombocytosis; SLD, single lineage dysplasia; U, unspecified; WHO, World Health Organization.